Sage Therapeutics Q3 EPS $(3.37) Vs $(2.31) Last Year, Sales $2.72M Miss $4.62M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics reported Q3 losses of $(3.37) per share, a 45.89% decrease from the same period last year. The company's quarterly sales were $2.72 million, missing the analyst consensus estimate of $4.62 million by 41.21%. However, this is a 56.18% increase over sales of $1.74 million the same period last year.
November 07, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics reported a larger than expected loss and missed sales estimates for Q3. Despite a YoY increase in sales, the results may negatively impact investor sentiment.
Sage Therapeutics reported a larger loss per share than the same period last year and missed sales estimates. Despite a YoY increase in sales, the missed estimates and increased losses could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100